drugset / Trial / NCT01269476
Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomised, double-blind, group-sequential, placebo-controlled, safety and pharmacokinetic study in healthy, aged volunteers. Objectives: 1. to confirm the previously reported safety profile of oral SNX-001 after single and multiple doses of 3.6, 7.2 or 10.8 mg compared to placebo 2. to establish SNX-001 pharmacokinetic profile.
Timeline
- Start
- 2009-12
- Primary completion
- 2010-06
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | METHANESULFONYL FLUORIDE | Small molecule | 3.6 mg | Oral |
| Subject | METHANESULFONYL FLUORIDE | Small molecule | 7.2 mg | Oral |
| Subject | METHANESULFONYL FLUORIDE | Small molecule | 10.8 mg | Oral |
Indications
No indication recorded.